PolyQ disease: misfiring of a developmental cell death program?
ES Blum, AR Schwendeman, S Shaham - Trends in cell biology, 2013 - cell.com
Polyglutamine (polyQ) repeat diseases are neurodegenerative ailments elicited by
glutamine-encoding CAG nucleotide expansions within endogenous human genes. Despite …
glutamine-encoding CAG nucleotide expansions within endogenous human genes. Despite …
Studying polyglutamine diseases in Drosophila
Polyglutamine (polyQ) diseases are a family of dominantly transmitted neurodegenerative
disorders caused by an abnormal expansion of CAG trinucleotide repeats in the protein …
disorders caused by an abnormal expansion of CAG trinucleotide repeats in the protein …
AAV vectors for retinal and CNS gene therapy
A Scaria, J Sullivan - US Patent 10,982,228, 2021 - Google Patents
2022-01-07 First worldwide family litigation filed litigation Critical https://patents. darts-ip.
com/? family= 53189202&utm_source= google_patent&utm_medium …
com/? family= 53189202&utm_source= google_patent&utm_medium …
Differential changes in postsynaptic density proteins in postmortem Huntington's disease and Parkinson's disease human brains
C Fourie, E Kim, H Waldvogel, JM Wong… - Journal of …, 2014 - Wiley Online Library
NMDA and AMPA‐type glutamate receptors and their bound membrane‐associated
guanylate kinases (MAGUKs) are critical for synapse development and plasticity. We …
guanylate kinases (MAGUKs) are critical for synapse development and plasticity. We …
Quality control in Huntington's disease: A therapeutic target
Huntington's disease (HD) is a fatal autosomal dominantly inherited brain disease caused
by excessively expanded CAG repeats in gene which encodes huntingtin protein. These …
by excessively expanded CAG repeats in gene which encodes huntingtin protein. These …
Colorimetric determination of cysteamine based on the aggregation of polyvinylpyrrolidone-stabilized silver nanoparticles
A simple, colorimetric and visual method is described for the determination of cysteamine
(CA) using polyvinylpyrrolidone-stabilized silver nanoparticles (PVP-AgNPs) as a …
(CA) using polyvinylpyrrolidone-stabilized silver nanoparticles (PVP-AgNPs) as a …
Aberrant palmitoylation in Huntington disease
SS Sanders, MR Hayden - Biochemical Society Transactions, 2015 - portlandpress.com
Huntington disease (HD) is an adult-onset neurodegenerative disease caused by a CAG
expansion in the HTT gene. HD is characterized by striatal atrophy and is associated with …
expansion in the HTT gene. HD is characterized by striatal atrophy and is associated with …
Selective cognitive impairment in the YAC128 Huntington's disease mouse
SP Brooks, N Janghra, GV Higgs, Z Bayram-Weston… - Brain research …, 2012 - Elsevier
People with HD have a demonstrated early extra-dimensional set-shifting deficit. In the
present study, we use a novel water T-maze set-shifting procedure and demonstrate its …
present study, we use a novel water T-maze set-shifting procedure and demonstrate its …
Cognitive dysfunction in H untington's disease: mechanisms and therapeutic strategies beyond BDNF
M Puigdellívol, A Saavedra… - Brain Pathology, 2016 - Wiley Online Library
One of the main focuses in Huntington's disease (HD) research, as well as in most
neurodegenerative diseases, is the development of new therapeutic strategies, as currently …
neurodegenerative diseases, is the development of new therapeutic strategies, as currently …
Selective degeneration in YAC mouse models of Huntington disease
Huntington disease (HD) is one of at least nine polyglutamine disorders caused by a CAG
expansion in the coding region of a disease-causing gene. These disorders are …
expansion in the coding region of a disease-causing gene. These disorders are …